<DOC>
	<DOC>NCT00477373</DOC>
	<brief_summary>To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode according to DSM IV (APA 1994) over a 12 weeks period of treatment. To evaluate the clinical safety of Di-valproate.</brief_summary>
	<brief_title>Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>In or out patients Patients with a current diagnosis of Bipolar I Disorder according to DSM IV (296) Patients suffering from a current manic episode or mixed episode Patients who participated in a clinical trial within the three preceding months Patients with a history of valproate intolerance defined as valproate discontinuation due to medically significant adverse effects. Patients with a CNS neoplasm, demyelinating disease, degenerative neurological disorder, active CNS infection or any progressive disorder Patients with a history of seizure disorder, cerebral vascular disease, structural brain damage from trauma, clinically significant focal neurological abnormalities, known EEG with frank paroxysmal activity or a known CT scan of the brain demonstrating gross structural abnormalities Patients with uncontrolled gastrointestinal, renal, hepatic, endocrine, cardiovascular, pulmonary, immunological or hematological disease Patients with acute or chronic hepatitis Patients with current or past pancreatitis Patients with recent history (3 months or less) of substance or alcohol dependence according to DSM IV Pregnancy or lactation. Women of child bearing age should be using a reliable contraceptive method Patients that require more than 325 mg of aspirin per day Patients with a medical condition which requires the continuous use of medication which could interfere with the evaluation of safety or efficacy of valproate : anticonvulsant or anticoagulant therapy, MAO inhibitors, zidovudine Patients having received any depot neuroleptic within six weeks prior to baseline Patients who received antidepressant drugs within 5 days before baseline and patients who received fluoxetine within 20 days Patients judged by the investigator to have serious risk of suicide Patients necessitating an Electro Convulsive Therapy The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>